INCY - Incyte - Stock Price & Dividends

Incyte Corporation is a biopharmaceutical company that focuses on discovering, developing, and commercializing innovative therapies for various diseases, primarily in the areas of hematology, oncology, inflammation, and autoimmunity.

The company has a diverse portfolio of approved products, including JAKAFI (ruxolitinib), which treats myelofibrosis, polycythemia vera, and acute graft-versus-host disease. Additionally, Incyte offers MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma, PEMAZYRE (pemigatinib) for certain types of cancer, ICLUSIG (ponatinib) for chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia, and ZYNYZ (retifanlimab-dlwr) for metastatic or recurrent locally advanced Merkel cell carcinoma.

Incyte also has a robust pipeline of clinical-stage products, including retifanlimab, which is being evaluated in Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer. Other pipeline products include axatilimab, an anti-CSF-1R monoclonal antibody being developed for chronic graft-versus-host disease, and several other investigational therapies targeting various types of cancer and inflammatory diseases.

The company has established strategic partnerships with several leading pharmaceutical companies, including Novartis, Lilly, Agenus, Merus, MacroGenics, and Syndax, to advance its research and development efforts. Incyte sells its products to a range of customers, including specialty, retail, and hospital pharmacies, distributors, and wholesalers.

Incyte Corporation, formerly known as Incyte Genomics Inc, was renamed in March 2003. The company is committed to improving patient outcomes by developing innovative, life-changing medicines. For more information, visit their website at https://www.incyte.com.